Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

"Our project is innovative in its use of advanced epigenetic techniques combined with a novel preclinical model of PDAC survivorship," Dr. Arneson-Wissink said. "Together, these tools allow us to ...

Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...

Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cancer cachexia therapeutics market and it is poised to grow by USD 568.85 million during 2019-2023, progressing at a CAGR of 6% during the ...

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

The dietary supplement melatonin does not improve the symptoms of cachexia in patients with advanced cancer, according to a study published online February 25 in the Journal of Clinical Oncology.